Monday’s approval of the Pandemic Agreement resolution follows a more than three-year process, launched by governments during the COVID-19 pandemic, to negotiate the world’s first such accord to address the gaps and inequities in preventing, preparing for and responding to pandemics. This watershed agreement was adopted under Article 19 of the WHO Constitution. It aims to foster stronger collaboration and cooperation among countries, international organizations like WHO, civil society, the private sector and other stakeholders to prevent pandemics occurring in the first place, and to better respond in the event of a future pandemic crisis.
The Pandemic Agreement and the resolution calling for its adoption will be taken up by the full plenary of the World Health Assembly on Tuesday, 20 May. Immediately after, there will be a High-Level segment featuring statements from Heads of States of multiple countries.
The resolution sets out several steps for taking the world forward and preparing for the Pandemic Agreement’s implementation. It includes the launch of a process to draft and negotiate an annex to the Agreement that would establish a Pathogen Access and Benefit Sharing system (PABS) through an Intergovernmental Working Group (IGWG). The result of this process will be considered at next year’s World Health Assembly. Once the Assembly adopts the PABS annex, the Pandemic Agreement will then be open for signature and consideration of ratification, including by national legislative bodies. After 60 ratifications, the Agreement will enter into force.
According to the Agreement, pharmaceutical manufacturers participating in the PABS system will play a key role in equitable and timely access to pandemic-related health products by making available to WHO “rapid access targeting 20% of their real time production of safe, quality and effective vaccines, therapeutics, and diagnostics for the pathogen causing the pandemic emergency.” The distribution of these products to countries will be carried out on the basis of public health risk and need, with particular attention to the needs of developing countries and those supported through the GSCL.
Dr Tedros thanked the Bureau of the Intergovernmental Negotiating Body (INB) that coordinated and facilitated the process to draft and negotiate the Pandemic Agreement. The WHO Director-General also praised the tireless work and excellence of the WHO Secretariat team that supported the Bureau and Member States, led by Dr Michael Ryan and Dr Jaouad Mahjour.
The INB was established in December 2021, at a special session of the World Health Assembly. WHO Member States were tasked to develop a convention, agreement or other international instrument under the WHO Constitution to strengthen pandemic preparedness, prevention and response. Members of the INB Bureau that guided the process were Co-Chairs Ms Precious Matsoso (South Africa) and Ambassador Anne-Claire Amprou (France), and Vice-Chairs Ambassador Tovar da Silva Nunes (Brazil), Ambassador Amr Ramadan (Egypt), Dr Viroj Tangcharoensathien (Thailand); and Ms Fleur Davies (Australia). Past members included former Co-Chair, Mr Roland Driece (the Netherlands), and former Vice-Chairs Ambassador Honsei Kozo (Japan), Mr Kazuho Taguchi (Japan), and Mr Ahmed Soliman (Egypt).
Read More Details
Finally We wish PressBee provided you with enough information of ( Member States approve WHO Pandemic Agreement in World Health Assembly Committee, paving way for its formal adoption )
Also on site :